The global transfection reagents and equipment market size reached USD 1,037 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,834 Million by 2033, exhibiting a growth rate (CAGR) of 6.5% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 1,037 Million |
Market Forecast in 2033
|
USD 1,834 Million |
Market Growth Rate (2025-2033) | 6.5% |
Transfection reagents and equipment help modulate gene expression in eukaryotic cells in vitro and in vivo. They allow researchers to generate stable cell lines and introduce deoxyribonucleic acid (DNA) plasmids possessing gene inserts for expression and small interfering RNA (siRNA). They are currently being used as viable analytical tools for protein synthesis, cell growth and development, and facilitating the study of genetic functions. Besides this, as they provide cost-effective and rapid production of recombinant human therapeutic proteins in sufficient quantities, transfection reagents and equipment are also gaining traction in producing r-proteins, antibodies, and viral vectors for vaccines.
Due to the outbreak of coronavirus disease (COVID-19) globally, governing agencies of numerous countries are focusing on accelerating the vaccination drive. However, due to the emergence of new variants, the protection and immunity that these vaccines provide are short-lived. As a result, there is a rise in the need of transfection reagents and equipment to develop innovative strategies or alternatively repurpose existing treatments to fight against virus infection. Apart from this, rapid detection of new cancer variants, coupled with the escalating demand for precision medicine and high-quality oncology care, are driving the adoption of transfection reagents and equipment in cancer research and drug development. Moreover, the emerging use of gene therapies to treat rare diseases caused by genetic problems is impelling the market growth. Furthermore, due to the growing number of fatal road accidents across the globe, there is a significant rise in the demand for tissue engineering to develop functional substitutes for damaged tissues. This, in turn, is propelling the market growth. Besides this, recent advancements in transfection technologies, along with increasing investments in pharmaceutical and biotechnology sectors, are anticipated to drive the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global transfection reagents and equipment market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on product, technology, application and end user.
Breakup by Product:
Breakup by Technology:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Bio-Rad Laboratories Inc., Lonza Group AG, MaxCyte Inc., Merck KGaA, Mirus Bio LLC, OriGene Technologies Inc., PerkinElmer Inc., Polyplus-transfection SA, Promega Corporation, PromoCell GmbH, Qiagen N.V. and Thermo Fisher Scientific Inc.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Segment Coverage | Product, Technology, Application, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Bio-Rad Laboratories Inc., Lonza Group AG, MaxCyte Inc., Merck KGaA, Mirus Bio LLC, OriGene Technologies Inc., PerkinElmer Inc., Polyplus-transfection SA, Promega Corporation, PromoCell GmbH, Qiagen N.V. and Thermo Fisher Scientific Inc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global transfection reagents and equipment market was valued at USD 1,037 Million in 2024.
We expect the global transfection reagents and equipment market to exhibit a CAGR of 6.5% during 2025-2033.
The increasing demand for transfection reagents and equipment to produce r-proteins, antibodies, and viral vectors for vaccines is primarily driving the global transfection reagents and equipment market.
The sudden outbreak of the COVID-19 pandemic and the emergence of new variants have led to the widespread adoption of transfection reagents and equipment for accelerating the vaccination drive and protecting the immunity of individuals.
Based on the product, the global transfection reagents and equipment market has been divided into reagents and equipment, where reagents currently exhibit a clear dominance in the market.
Based on the technology, the global transfection reagents and equipment market can be categorized into biochemical based transfection, physical transfection, and viral-vector based transfection. Currently, biochemical based transfection accounts for the majority of the total market share.
Based on the application, the global transfection reagents and equipment market has been segregated into biomedical research, protein production, and therapeutic delivery. Among these, biomedical research currently holds the largest market share.
Based on the end user, the global transfection reagents and equipment market can be bifurcated into pharmaceutical and biotechnology companies and academics and research institutes. Currently, academics and research institutes exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global transfection reagents and equipment market include Bio-Rad Laboratories Inc., Lonza Group AG, MaxCyte Inc., Merck KGaA, Mirus Bio LLC, OriGene Technologies Inc., PerkinElmer Inc., Polyplus-transfection SA, Promega Corporation, PromoCell GmbH, Qiagen N.V., and Thermo Fisher Scientific Inc.